CSA & ampTISC 20 19 Press Conference Site
In 20 13, Professor Wang Yongjun, a scholar from China, announced the results of CHANCE research to the world for the first time at the International Stroke Conference, that is, compared with aspirin monotherapy, clopidogrel combined with aspirin for 2 1 day, followed by clopidogrel monotherapy until the 90th day, can significantly reduce the risk of stroke recurrence in patients with mild ischemic stroke and transient cerebral ischemia (HR-NICE) by 32% without increasing it. This research result has caused a sensation in international academic circles, and its scientific and forward-looking nature has been confirmed by other large international research institutions. This time, China led the world. Based on this evidence, 20 14 rewrote the "Guidelines for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack in China", which greatly increased the proportion of double antibody treatment for HR-NICE patients in China and reduced the risk of stroke recurrence. Subsequently, the international guide was updated according to the results of CHANCE research. Six years later, the team led by Professor Wang Yongjun set sail again to challenge the more accurate treatment of ischemic stroke. CHANCE-2 research was officially launched on June 29th, which will be another milestone research, which will surely make China occupy the commanding heights in this academic field and bring more vitality to the majority of stroke patients.
Opportunity II research officially began.
There are more than130,000 stroke patients in China, and there are 2.5 million new strokes every year. It is the leading cause of death in China, with the characteristics of high morbidity, high mortality, high disability rate and high recurrence rate. Among them, HR-NICE patients have a very high risk of short-term recurrent stroke. Antiplatelet therapy, together with lowering blood pressure and blood lipid, constitutes three cornerstones to prevent recurrence and reduce the risk of death and other macrovascular events. CHANCE research based on China population shows that dual antiplatelet therapy with aspirin and clopidogrel can reduce the relative risk of stroke recurrence by 32% within 90 days without increasing the risk of bleeding in patients with acute HR-NICE. The international population study published on 20 18 once again confirmed that clopidogrel and aspirin double antibody therapy is superior to traditional single drug therapy for patients with acute HR-NICE. At the same time, it is pointed out that the treatment time should be strictly controlled, indicating that the 2 1 day double antibody scheme in CHANCE research is more suitable for HR-NICE patients.
However, under the enhanced double antibody regimen of opportunity, HR-NICE patients still have a residual recurrence risk of 8.7%. Especially, the LoF carrying rate of CYP2C 19 in China population was as high as 58.8%, which reduced the concentration of active metabolites of chlorbiuret in this population. Based on this, CHANCE-2 designed and studied CYP2C 19 LoF carriers, and carried out drug screening at the genetic level to realize individualized and precise treatment strategies. Moreover, the drugs used in the CHANCE-2 research were all developed and produced in China, and the first batch of products passed the consistency evaluation, namely Taijia (clopidogrel bisulfate tablets) and Taiyi (Tigray tablets). Realize China's own medicine, support China's clinical research, and finally serve China patients' scientific research autonomy.
From the absence of China people on the international stage to the surprise of China's speech at the international conference, Professor Wang Yongjun and his team have worked hard for more than ten years, contributing China wisdom and China's plan to solve the human cerebrovascular problem. Scientific research results have a positive effect on the formulation of various disease guidelines, and can also promote the rapid development of China's biomedical industry, which is of great significance to the overall improvement of China's medical level and even the world's advanced level.
Research and use of drugs
The drugs used in this study were provided by Xinlitai Company. Taijia actively responded to the national procurement policy and became the first successful bidder for clopidogrel bisulfate tablets, actively reducing the drug price by 58%, and the daily treatment cost was only 3. 18 yuan/day, which greatly improved the accessibility of antiplatelet drugs in China and benefited more patients. Another research drug is a new generation of P2Y 12 inhibitor, which is newly introduced by Xinlitai Company, which increases the choice of clinical drugs.
About Xinlitai Company
Xinlitai Company was established in 1998 and listed on Shenzhen Stock Exchange in 2009. Is a leading enterprise in the field of cardiovascular and cerebrovascular diseases, with a number of core intellectual property rights and independent innovation in China. Clopidogrel bisulfate tablets, one of the research drugs of CHANCE-2, responded positively to the national procurement policy and became the first winning bid. The drug price was reduced by 58%, and the daily treatment cost was only 3. 18 yuan/day, which greatly improved the accessibility of antiplatelet drugs in China and benefited more patients. Xinlitai Company also introduced a new generation of P2Y 12 inhibitor, teglol, which is also the research drug in this study. The two dosage forms increase the choice of clinical drugs. Xinlitai Company firmly believes that solid evidence-based medical evidence is the basis of clinical practice. In this company, both generic drugs and original drugs, together with cardiovascular experts, have accumulated a lot of evidence-based medical evidence from patients in China. A team with good evidence-based medical evidence in the past. China's first and leading bivalirudin original research, leading domestic academic research, and the international multi-center RCT clinical trial-Guangming trial, which cooperated with Academician Han Yaling, included more than 2,000 PPCI patients; It was successfully published in JAMA magazine, so the China guidelines for percutaneous coronary intervention (20 16) were rewritten. The results of the "Phase IV Study of Alisartan Ester HTN" with Professor Huo Yong from Peking University First Hospital and Professor Sun Ningling from Peking University People's Hospital as PI will be announced soon this year. The "Clinical Study of Alisartan Ester CKD" in cooperation with Professor Chen Jianghua from the First Affiliated Hospital of Zhejiang University will be launched soon, and the study of patients with kidney disease will be carried out.
In the future, Xinlitai will continue to do its best to cooperate with clinical research experts in China and continue to develop China people's own clinical evidence. Promote China's scientific research level to the center of the world stage, and finally better serve China patients. We have been adhering to the concept of "beauty comes from sincerity", adhering to the core values of "patient-centered" and devoting ourselves to human health with excellent pharmaceutical products.